✦ LIBER ✦

3047 POSTER Resection of the primary tumour as an independent prognostic factor for survival in patients with advanced colorectal cancer. CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

✍ Scribed by M. Koopman; N.F. Antonini; G. Vreugdenhil; O.J.L. Loosveld; A. van Bochove; H.A.M. Sinnige; G.J.M. Creemers; M.E.T. Tesselaar; L. Mol; C.J.A. Punt

Book ID: 118625817
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 58 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70975-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6003 The correlation between Topoisomera

6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

✍ Koopman, M.; Knijn, N.; Richman, S.; Seymour, M.; Quirke, P.; van Tinteren, H.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 67 KB

A randomised phase III study on capecita

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

✍ Tol, J.; Koopman, M.; Rodenburg, C. J.; Cats, A.; Creemers, G. J.; Schrama, J. G 📂 Article 📅 2008 🏛 Oxford University Press 🌐 English ⚖ 76 KB

3000 ORAL Randomised phase III study of

3000 ORAL Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis

✍ J. Tol; M. Koopman; C.J. Rodenburg; A. Cats; G.J. Creemers; C.A.M. de Swart; F.L 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Survival Comparisons for Patients Presen

Survival Comparisons for Patients Presenting with Peritoneal Surface Disease and Undergoing Non-Curative Resection of the Primary Tumours in Advanced Colorectal Cancers

✍ Muhammad Imran Aslam; Ashish Kelkar; David Sharpe; John Stuart Jameson 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 131 KB

93 POSTER Phase I study of daily oral AZ

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; D. Jonker; M. Maclean; J. Wells; S. Mathews; J. Robertson; L. Seymour 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB